Uffe Vest Schneider’s research while affiliated with University of Copenhagen and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (56)


FIGURE 3 | (A) Prevalence of symptoms in participants infected with each virus, data from Week 40, 2023, to Week 46, 2024. Only responses from participants who have reported at least one symptom are included. Error bars represent a 95% confidence interval. (B) Distribution of the number of symptoms reported per positive sample, stratified by virus and ordered by median symptom count, from highest to lowest. n indicates the number of symptomatic individuals per virus.
FIGURE 4 | Top panel: prevalence of symptoms over time. Only symptomatic individuals who perform a sample from Week 40, 2023, to Week 46, 2024. Bottom panel: number of each symptom reported among individuals with a positive test at the time of sampling (Baseline), symptoms that were only reported at the time of sampling but were not present after 7-28 days (Gone at Follow-up), and those that were only reported at 7-28 days after the sample, but not at the time of sampling (New at Follow-up). Includes only individuals who answered both symptom questionnaires.
FIGURE 5 | Top panel shows the weekly incidence rate of SARS-CoV-2 in VMD (red line, left y-axis) and the weekly concentration of SARSCoV-2 RNA in wastewater surveillance (blue line, right y-axis), with the peak of both curves in the same level, both on logarithmic scales. Bottom panel shows SARS-CoV-2 variant composition in VMD samples during the study period. Data from Week 40, 2023, to Week 46, 2024.
FIGURE 6 | Prevalence of individual symptoms in participants infected with different SARS-CoV-2 subvariants. Only responses from participants who have reported at least one symptom are included. Error bars represent 95% confidence. Data from Week 24, 2023, to Week 46, 2024.
(Continued)
Virus Monitoring in Denmark: A Community‐Based Self‐Sampling System to Surveil Respiratory Viruses and Associated Symptoms
  • Article
  • Full-text available

March 2025

·

7 Reads

Journal of Medical Virology

Tine Graakjær Larsen

·

Jonathan R. Ginty

·

Randi Jessen

·

[...]

·

This study presents findings captured in the first 1.5 years of the Virus Monitoring in Denmark (VMD) surveillance system. It describes trends in respiratory viruses, related symptoms, and participant demographics and behaviors. VMD used self‐swabbing and self‐reported symptoms to monitor respiratory viruses in the general population. Participants were recruited via digital invitations to a representative sample of the population or through workplaces. Symptomatic participants could self‐swab and register their samples and report their symptoms via a dedicated smartphone web app. With 30 627 participants and 12 642 samples analyzed, VMD had a broad demographic representation. SARS‐CoV‐2 was the most frequently detected virus, with positivity rates peaking at over 50% in late 2023. Participants commonly self‐swabbed because of fever, cough, and rhinorrhea, with influenza A linked to the highest median number of symptoms. Participants only provided samples after reaching a specific symptom threshold, and participation affected the health‐seeking behaviors and work attendance of a few individuals. VMD continuously provided real‐time insights into respiratory virus trends and symptomatology in the general non‐healthcare‐seeking population. Its accessibility – available to anyone with a Danish identification number, a smartphone, and an invitation – highlights its potential as a pandemic preparedness tool.

Download


Prevalence of hepatitis C virus hypervariable region 1 insertions and their role in antibody evasion

October 2024

·

24 Reads

·

1 Citation

Hepatology

Background and Aims Chronic hepatitis C virus (HCV) infection afflicts around 50 million people globally, causing ~250,000 deaths yearly. An effective vaccine needs to overcome high viral diversity and HCV’s ability to evade neutralizing antibodies (NAbs). Rapid antigenic drift in the N-terminal motif of envelope protein E2, named hypervariable region 1 (HVR1), is critically involved in NAb evasion via an incompletely understood mechanism involving viral entry factors. The canonical length of HVR1 is 27 amino acids, but insertions of 2-4 amino acids was described in patients infected with genotype 1b. We aimed at determining whether HVR1 insertions may be underreported due to extreme HVR1 variability. Approach and Results We observed a 0.7% HVR1 insertion prevalence in routine NGS patient contigs. Thus, we performed direct sequence analysis of E1E2 sequences from 131 HCV infected patients. Interestingly, we observed that 3% of patients harbored viruses (genotype 1a, 2b, 3a) with dominant HVR1 insertions. Insertion of longer non-canonical HVR1s into HCV cell culture recombinants frequently caused loss of fitness. However, culture-viable viruses with HVR1 insertions were fully viable in vivo . Interestingly, in adapted genotype 1b recombinants with HVR1 insertions, we found internal HVR1 deletions, that increased antibody sensitivity, which surprisingly correlated more with reduced LDLr than reduced SR-BI dependency, indicating a role of LDLr in NAb evasion. Conversely, HVR1 insertions had no effect on receptor dependency, however, they modulated epitope-specific NAb sensitivity. Conclusions HVR1 insertion prevalence and NAb sensitivity modulation indicate they represent a mechanism by which HCV evades emerging NAbs during infection.







Figure 1. Immune evasion potential of BA.2.86 A) Spike mutations of SARS-CoV-2 variants BA.2, BA.5, XBB.1.5, EG.5.1, and
Figure S1. Cytopathic effect (CPE) of BA.2.86 induced on CaLu-3 cells and iGROV-1 cells four days post-246 inoculation with clinical sample material and Vero E6 cells four days post-inoculation with passage 1 virus 247 produced in CaLu-3 cells. The passage 2 CPE induced in Vero E6 cells were similar when using CaLu-3 or 248 iGROV-1 produced passage 1 virus. 249
Neutralisation of SARS-CoV-2 Omicron subvariants BA.2.86 and EG.5.1 by antibodies induced by earlier infection or vaccination

October 2023

·

243 Reads

·

2 Citations

Highly mutated SARS-CoV-2 Omicron subvariant BA.2.86 emerged in July 2023. We investigated the neutralisation of isolated virus by antibodies induced by earlier infection or vaccination. The neutralisation titres for BA.2.86 were comparable to those for XBB.1 and EG.5.1, by antibodies induced by XBB.1.5 or BA.4/5 breakthrough infection or BA.4/5 vaccination.


The impact of acute SARS-CoV-2 on testicular function including insulin-like factor 3 [INSL3] in men with mild COVID-19: A longitudinal study

July 2023

·

28 Reads

·

5 Citations

Andrology

Background: SARS-CoV-2 may affect the male reproductive system as it uses angiotensin-converting enzyme [ACE]2, which is expressed in testicular tissue, as an entry point into the cell. Few studies have evaluated the long-term effects of mild COVID-19 on testicular function, and INSL3 levels have not previously been assessed during acute SARS-CoV-2 infection. Objectives: To assess the impact of acute SARS-CoV-2 infection on testicular function including INSL3 and the presence of SARS-CoV-2 RNA in semen in non-hospitalised men with mild COVID-19. Materials and methods: This longitudinal study included 36 non-hospitalised SARS-CoV-2-positive men (median age 29 years). Inclusion was within seven days following a positive SARS-CoV-2 RT-PCR test. Reproductive hormone levels, semen parameters, and the presence of SARS-CoV-2 RNA in oropharyngeal and semen samples were assessed during acute SARS-CoV-2 infection (baseline) and at three- and six-month follow-up. Wilcoxon matched-pair signed-rank (two samples) test was used to assess time-related alterations in reproductive hormone levels and semen parameters. Results: Lower plasma testosterone [T] (total and calculated free [c-fT]) and higher LH concentrations were observed during acute SARS-CoV-2 infection (baseline) compared to three- and six-month follow-up. Consequently, ratios of c-fT/LH were lower at baseline compared to three- and six-month follow-up (P < 0.001 and P = 0.003, respectively). Concomitantly, lower INSL3 concentrations were observed at baseline compared to three-month follow-up (P = 0.01). The total number of motile spermatozoa was also lower at baseline compared to six-month follow-up (P = 0.02). The alterations were detected irrespective of whether the men had experienced SARS-CoV-2-related fever episodes or not. No SARS-CoV-2 RNA was detected in semen at any time point. Discussion and conclusion: This study showed a reduction in testicular function, which was for the first time confirmed by INSL3, in men mildly affected by SARS-CoV-2 infection. The risk of transmission of SARS-CoV-2 RNA via semen seems to be low. Febrile episodes may impact testicular function, but a direct effect of SARS-CoV-2 cannot be excluded. This article is protected by copyright. All rights reserved.


Citations (30)


... The Cepheid GeneXpert assay (Cepheid, Sunnyvale, CA) is a rapid, on-demand molecular diagnostic test that can identify and differentiate influenza A, influenza B, and RSV viruses on nasopharyngeal swabs. This real-time PCR test utilizes a single-use cartridge that contains all the necessary reagents, automating the preparation of nucleic acids from clinical samples, performing real-time PCR detection, and delivering multiple test results in approximately 32 min [8]. Although the Cepheid GeneXpert assay is rapid, it has some limitations, specifically the lack of nucleic acid enrichment and purification steps. ...

Reference:

Comparison of the Performances of the Accunome DXcellence and Cepheid GeneXpert Assays in Detecting Influenza A and B Viruses and Respiratory Syncytial Virus in Nasopharyngeal Swab
Evaluation of the analytical and clinical performance of two RT-PCR based point-of-care tests; Cepheid Xpert® Xpress CoV-2/Flu/RSV plus and SD BioSensor STANDARD™ M10 Flu/RSV/SARS-CoV-2
  • Citing Article
  • April 2024

Journal of Clinical Virology

... cn/ bcedb/ item/ jbrow se); and S1139 epitopes of beta-coronavirus or coronavirus show slight differences in amino acid sequence (Fig. S1). Thus, to determine how point mutations in S1139 or how other coronavirus-derived S1139 affect the binding ability of RNH1-S1139 elicited antibodies, we synthesized mutated S1139 peptides gathered from GISAID, including P1143L that occurs in Omicron subvariant BA.2.86, S1139 sequence of SARS-CoV-2 (W.T., Beta, Delta, Omicron), SARS-CoV, MERS-CoV, and more distantly related human and murine coronaviruses HCoV-HKU4, HCoV-HKU5, MHV, HCoV-OC43, HCoV-HKU1, HCoV-229E [44]. Antibody binding property is almost unaffected by point mutations within Sarbecovirus except for D1153Y (Fig. 2D). ...

Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1
  • Citing Article
  • November 2023

The Lancet Infectious Diseases

... [9], as expected from the cell-entry-enhancing P1143L mutation. Interestingly, authentic BA.2.86 established a primary infection from clinical sample material in human-derived cell lines CaLu-3 and iGROV-1, but not African Green Monkey-kidney-derived cell lines Vero E6, Vero/hSLAM, and VeroE6 expressing ACE-2 and TMPRSS2 [10]. ...

Neutralisation of SARS-CoV-2 Omicron subvariants BA.2.86 and EG.5.1 by antibodies induced by earlier infection or vaccination

... [62][63][64] It has also been shown that 4−6 months after recovery, there was a significant reduction in abnormal semen quality. [65][66][67] In this study, we compared semen samples Our data also demonstrated that in men recovered from SARS- ...

The impact of acute SARS-CoV-2 on testicular function including insulin-like factor 3 [INSL3] in men with mild COVID-19: A longitudinal study
  • Citing Article
  • July 2023

Andrology

... We aimed to identify clinical and paraclinical parameters from the initial evaluation of the patient that may suggest an unfavorable course of COVID-19. We also aimed to quantify the percentage of unfavorable evolutions in a population with lower vaccination coverage than the states where early studies were conducted [14][15][16][17][18][19] in order to assess the clinical severity of this disease in our region. ...

Clinical progression, disease severity, and mortality among adults hospitalized with COVID-19 caused by the Omicron and Delta SARS-CoV-2 variants: A population-based, matched cohort study
  • Citing Article
  • April 2023

... Evidence is accumulating that SARS-CoV-2 variants of concern (VoCs), which have been constantly evolving during the COVID-19 pandemic, underlie an increasing variability in the recognition by nucleocapsid-based detection systems [11][12][13][14][15][16][17]. Although several studies have investigated the sensitivity of automated Ag tests as a function of Ct values, there is little data on the influence of variants or especially Omicron-VoC subvariants [5,[18][19][20][21][22][23]. Thus, previous validations may not be predictive for the performance of RATs or automated Ag assays for detecting individuals infected with emerging VoCs [11,12,21,24]. ...

Evaluation of four laboratory-based high-throughput SARS-CoV-2 automated antigen tests compared to RT-PCR on nasal and oropharyngeal samples
  • Citing Article
  • May 2023

Journal of Clinical Virology

... 19 In addition to that, periodic drills and simulations should be conducted to reinforce and assess the proficiency of personnel in handling potential biohazards. 20 Maintaining a sufficient supply of high-quality PPE, coupled with continuous communication and updates on safety protocols, contributes to a secure working environment. 8 By prioritizing the safety of clinical laboratory personnel, healthcare systems can bolster their resilience during pandemics, safeguarding the well-being of essential frontline workers crucial to the diagnostic and monitoring processes. ...

Viral epidemic preparedness: A perspective from 5 clinical microbiology laboratory in Europe
  • Citing Article
  • April 2023

Clinical Microbiology and Infection

... Amongst people who inject drugs, changes in clones of bacteria and the prevalence of resistant organisms such as methicillin-resistant Staphylococcus aureus (MRSA) are of increasing concern. Clonal expansion of S. aureus and Streptococcus pyogenes have contributed to outbreaks of acute infections in people who inject drugs in the United Kingdom and Europe [65][66][67]. Furthermore, acute infections due to MRSA have been increasingly reported in people who inject drugs in North America and Europe, with concerns around shifts in population structures of MRSA clones [66,68,69]. ...

Whole genome sequencing reveals two genetically distinct MRSA outbreaks among people who inject drugs and homeless people in Copenhagen
  • Citing Article
  • April 2023

Apmis

... Although our study observed increased neutralizing titers against Omicron variants, repeated Omicron PVIs could not completely dampen the immune imprinting, consistent with earlier reports 17 . This limitation may be attributed to the relatively small sample size for repeated Omicron post-vaccination infections (PVIs) and the lower disease severity of these infections, which may influence the strength of the stimulated immune response 31 . Moreover, most participants received three to five doses of the ancestral monovalent vaccine; thus, multiple exposures to ancestral SARS-CoV-2 antigens may have induced deep immune imprinting 23,32 . ...

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination

EBioMedicine

... Thus, a classification has been proposed based on the cause (infection/vaccination) and time of the manifestation of symptoms after vaccination [150]. Furthermore, SARS-CoV-2 mRNA sequence analysis from blood and tissue samples can help to identify the cause of disorders in affected patients, given that the spike mRNA COVID-19 vaccine sequences are only~70% identical to the wild-type viral spike [151]. ...

SARS‐CoV ‐2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID ‐19 vaccination

Apmis